News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,423 Results
Type
Article (13829)
Company Profile (101)
Press Release (252493)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88078)
Career Advice (465)
Deals (15346)
Drug Delivery (67)
Drug Development (36608)
Employer Resources (49)
FDA (6301)
Job Trends (6204)
News (150272)
Policy (14047)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (38)
Alliances (23244)
ALS (39)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (46)
Approvals (6339)
Artificial intelligence (115)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (653)
Cardiovascular disease (74)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (91)
Cervical cancer (4)
Clinical research (30974)
Collaboration (362)
Compensation (166)
Complete response letters (17)
COVID-19 (760)
CRISPR (23)
C-suite (133)
Cystic fibrosis (39)
Data (695)
Denatured (15)
Depression (10)
Diabetes (84)
Diagnostics (1327)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (68)
Drug shortages (12)
Duchenne muscular dystrophy (39)
Earnings (32365)
Editorial (14)
Employer branding (4)
Employer resources (43)
Events (37668)
Executive appointments (407)
FDA (6786)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (221)
Gene editing (41)
Generative AI (9)
Gene therapy (103)
GLP-1 (351)
Government (1305)
Grass and pollen (3)
Guidances (61)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (37)
Indications (14)
Infectious disease (795)
Inflammatory bowel disease (58)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5887)
IRA (29)
Job creations (2052)
Job search strategy (373)
Kidney cancer (6)
Labor market (14)
Layoffs (183)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (88)
Lymphoma (57)
Machine learning (4)
Management (16)
Manufacturing (172)
MASH (34)
Medical device (1278)
Medtech (1280)
Mergers & acquisitions (9677)
Metabolic disorders (269)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (25)
Neuropsychiatric disorders (8)
Neuroscience (587)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (153)
Opinion (119)
Ovarian cancer (22)
Pain (58)
Pancreatic cancer (17)
Parkinson's disease (47)
Partnered (7)
Patents (127)
Patient recruitment (30)
Peanut (10)
People (29009)
Pharmaceutical (64)
Pharmacy benefit managers (12)
Phase I (8062)
Phase II (13105)
Phase III (11758)
Pipeline (536)
Policy (74)
Postmarket research (1401)
Preclinical (3237)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (175)
Real estate (2637)
Recruiting (17)
Regulatory (10156)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (38)
Series A (39)
Series B (15)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (37)
The Weekly (30)
Vaccines (159)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (24)
Last 7 days (338)
Last 30 days (1049)
Last 365 days (11624)
2025 (4268)
2024 (12501)
2023 (14247)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (58)
Arkansas (3)
Asia (20170)
Australia (2618)
California (1854)
Canada (956)
China (255)
Colorado (72)
Connecticut (73)
Delaware (62)
Europe (39573)
Florida (357)
Georgia (40)
Idaho (9)
Illinois (206)
India (16)
Indiana (138)
Iowa (1)
Japan (101)
Kansas (60)
Kentucky (13)
Louisiana (2)
Maine (2)
Maryland (273)
Massachusetts (1600)
Michigan (30)
Minnesota (99)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (9)
New Hampshire (6)
New Jersey (812)
New Mexico (7)
New York (547)
North Carolina (409)
North Dakota (2)
Northern California (770)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (475)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (3)
Southern California (778)
Tennessee (36)
Texas (247)
United States (7716)
Utah (36)
Virginia (81)
Washington D.C. (32)
Washington State (127)
Wisconsin (19)
266,423 Results for "bioray pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
February 10, 2025
·
2 min read
FDA
Clinical Trial Application (IND) for BioRay Pharmaceutical’s BR105 Injection Receives U.S. FDA Approval
BioRay Pharmaceutical Co., Ltd. announced on October 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration.
October 24, 2023
·
2 min read
Drug Development
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
BioRay Pharmaceutical Co., Ltd. announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate targeting LIV-1 for the treatment of advanced malignant tumors.
November 7, 2023
·
2 min read
Policy
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
Recently, BioRay Pharmaceutical Co., Ltd. announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection, indicated for the treatment of CD20-positive diffuse large B-cell lymphoma, was officially approved for marketing by the National Medical Products Administration.
September 13, 2023
·
2 min read
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
BioRay Pharmaceutical Co., Ltd. announced that the Investigational New Drug application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration .
May 24, 2023
·
2 min read
Biotech Beach
Bioray Inc. Releases New Products for Teens at Expo West 2023 in Anaheim
Bioray Inc., The Natural Detox Company, is launching RAYZ ® for teens at Natural Products Expo West 2023 at the Anaheim Convention Center March 9th through March 11th , 2023.
March 3, 2023
·
1 min read
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
Nascent Biotech, Inc. is pleased to announce that the Company has received a payment totaling USD $750,000 from BioRay Pharmaceutical, Ltd.
February 23, 2022
·
3 min read
Press Releases
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
May 5, 2025
·
11 min read
Business
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent’s Pritumumab
Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech has entered into a license agreement with BioRay Pharmaceutical Co Ltd
May 19, 2021
·
4 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
1 of 26,643
Next
